

Gut-testis axis: microbiota-(n-3) PUFA improving semen quality in type 1 diabetes

Running title: Gut microbiota improves semen quality in T1D

Yanan Hao^{1,2,3#}, Yanni Feng^{4#}, Xiaowei Yan^{1,2#}, Liang Chen^{1#}, Ruqing Zhong^{1#},
Xiangfang Tang¹, Wei Shen², Qingyuan Sun⁵, Zhongyi Sun⁶, Yonglin Ren³, Hongfu
Zhang^{1,3*}, Yong Zhao^{1,3*}

Affiliations:

¹State Key Laboratory of Animal Nutrition, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, P. R. China

²College of Life Sciences, Qingdao Agricultural University, Qingdao 266109, P. R. China.

³College of Science, Health, Engineering and Education, Murdoch University, Perth 6150, Australia.

⁴College of Veterinary Medicine, Qingdao Agricultural University, Qingdao 266109, P. R. China.

⁵Fertility Preservation Lab, Reproductive Medicine Center, Guangdong Second Provincial General Hospital, Guangzhou, 510317, P. R. China.

⁶Urology Department, Shenzhen university general hospital, Shenzhen 518055, P. R. China.

These authors contributed equally

*Correspondence

Yong Zhao, Ph.D., Professor
State Key Laboratory of Animal Nutrition
Institute of Animal Sciences

30 Chinese Academy of Agricultural Sciences
 31 Beijing 100193, P. R. China
 32 Tel: +86-10-62819432
 33 Email: yzhao818@hotmail.com; Yong.Zhao@murdoch.edu.au
 34 ***Co-correspondence**
 35 Hongfu Zhang, Ph.D., Professor
 36 State Key Laboratory of Animal Nutrition
 37 Institute of Animal Sciences
 38 Chinese Academy of Agricultural Sciences
 39 Beijing 100193, P. R. China
 40 Tel: +86-10-62819432
 41 Email: zhanghongfu@caas.cn

Abstract

Gut dysbiosis and type 1 diabetes (T1D) are closely related, and gut dysbiosis and male infertility are correlated, too. Moreover, most male T1D patients are of active reproductive age. Therefore, it is crucial to explore possible means for improving their semen quality. Here, we found that fecal microbiota transplantation (FMT) from alginate oligosaccharide (AOS) improved gut microbiota (A10-FMT) significantly decreased blood glucose and glycogen, and increased semen quality in streptozotocin-induced T1D subjects. A10-FMT improved T1D-disturbed gut microbiota, especially the increase in small intestinal *lactobacillus*, and blood and testicular metabolome to produce n-3 polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) to ameliorate spermatogenesis and semen quality. Moreover, A10-FMT can improve spleen and liver function to strengthen the systemic environment for sperm development. FMT from gut microbiota of control animals (Con-FMT) produced some beneficial effects; however, to a smaller extent. Thus, AOS improved gut microbiota may be a useful protocol for improving semen quality and male fertility in T1D patients.

Keywords: Type 1 diabetes, A10-FMT, blood glucose, semen quality, DHA, EPA

59 **Importance**

60 Clinical data suggest that male reproductive dysfunction especially infertility is a
 61 critical issue for type 1 diabetic patient (T1D) because most of them are at the
 62 reproductive age. Gut dysbiosis is involved in T1D related male infertility. However,
 63 improved gut microbiota can be used to improve spermatogenesis and male fertility in
 64 T1D remains incompletely understood. We discovered that alginate oligosaccharide-
 65 improved gut microbiota (A10-FMT) significantly ameliorated spermatogenesis and
 66 semen quality. AOS-improved gut microbiota (specific microbes) may serve as a
 67 novel, promising therapeutic approach for the improvement of semen quality and
 68 male fertility in T1D patients.

69 Introduction

70 Type 1 diabetes (T1D), one of the most common metabolic disorders in children and
 71 young adults, is a multifactorial, immune-mediated disease that is characterized by the
 72 progressive destruction of autologous insulin-producing beta cells in the pancreas, and
 73 an increase in blood glucose levels (hyperglycemia)¹⁻³. Diabetic hyperglycemia leads
 74 to further disorder, including cardiovascular disease, neuropathy, nephropathy,
 75 retinopathy, and male impotence. Moreover, clinical data from males with
 76 hyperglycemia-induced reproductive dysfunction are reported in most T1D studies⁴.
 77 This increase in diabetes in young persons is of great concern as it will increase
 78 fertility related disorders during their reproductive lifespan⁵. Furthermore, the
 79 frequency of diabetes mellitus (DM) in males is higher than in females, and the
 80 incidence of infertility among diabetic males is more common, which will likely
 81 contribute to the reduction of global birth rates and fertility⁴. Many investigations
 82 have found DM-induced male infertility at multiple levels, such as changes in
 83 spermatogenesis, testes, ejaculatory function and libido^{5,6}. Additionally, cross-
 84 sectional studies reported that at the time of infertility diagnosis, young men are
 85 already less healthy than their fertile peers which suggests that male reproductive and
 86 somatic health are tightly correlated⁷.

87 Although T1D has a strong genetic basis, epigenetic and environmental factors
 88 (hygiene, antibiotic use, and diet) are involved in its development^{2,8}. Furthermore, all
 89 of these potential environmental risk factors are related to the intestine and its
 90 microbiota. Specific alterations in the diversity of intestinal microflora have been
 91 reported to be one characteristic of diabetic patients by the epidemiological
 92 investigations⁹⁻¹¹. Interaction of the gut microbes with the innate immune system
 93 plays vital roles in the development of T1D⁸. It has been reported that a reduction in

bacterial and functional diversity, and community stability are found in preclinical T1D patients, on the other hand *Bacteroidetes* is dominated¹²⁻¹⁵. The presence of small intestinal *Prevotella* are known to be inversely related to pancreatic beta cell function, however small intestinal *Desulfovibrio* are involved in preserved beta cell function⁸.

Very recently, it has been established that the gut microbiota plays crucial roles in spermatogenesis and male fertility¹⁶⁻¹⁹. Studies demonstrate a strong link between testicular function and the regulation of gut microbiota via host metabolomes, as beneficial microbiota have been shown to significantly improve busulfan impaired spermatogenesis and semen quality^{17,18}. Since noting the high incidence of infertility in T1D male patients, many investigators have tried to improve the semen quality and fertility in T1D induced animal models^{20,21}. It is reported that resveratrol attenuates reproductive alterations in T1D-induced rats with improvements in glycemic level, sperm quantitative and qualitative parameters, and the hormonal profile²⁰. Liu et al., found that metformin ameliorates testicular damage (90% of male DM patients have varying degrees of testicular dysfunction) in male mice with streptozotocin (STZ)-induced T1D through the PK2/PKR Pathway²¹. However, it is unknown whether impaired spermatogenesis and semen quality in the T1D condition can be improved by FMT or specific microbes. Therefore, this study aimed to explore possible improvements in spermatogenesis and semen quality made by alginate oligosaccharide (AOS) benefited microbiota which have previously been found to ameliorate busulfan or high fat diet disrupted spermatogenesis and male fertility.

Materials and Methods

Study design:

All animal procedures used in this study were approved by the Animal Care and

Use Committee of the Institute of Animal Sciences of Chinese Academy of Agricultural Sciences (IAS2020-106). Mice were maintained in specific pathogen-free (SPF) environment under a light: dark cycle of 12:12 h, at a temperature of 23 °C and humidity of 50%–70%; they had free access to food (chow diet) and water^{17,18,22}.

Experiment I: Mouse small intestine microbiota collection^{17,18}. Three-week-old ICR male mice were dosed with ddH₂O as the control or AOS 10 mg/kg BW via oral gavage (0.1 ml/mouse/d). AOS dosing solution was freshly prepared on a daily basis and delivered every morning for three weeks. There were two groups (30 mice/treatment): (1) Control (ddH₂O); (2) A10 (AOS 10 mg/kg BW). After three weeks treatment, the animals were maintained on regular diet for three more days (no treatment). Then the mice were humanely euthanized to collect small intestinal luminal content (microbiota).

Experiment II: STZ treatment and microbiota transplants (FMT)^{17,18,23,24}. The small intestine luminal content (microbiota) from each group was pooled and homogenized, diluted 1:1 in 20% sterile glycerol (saline) and frozen. Before inoculation, fecal samples were diluted in sterile saline to a working concentration of 0.05 g/ml and filtered through a 70-µm cell strainer. Five-week-old ICR male mice were used in current investigation. There were four treatment groups (30 mice/treatment): (1) Control (Regular diet plus Saline); (2) STZ (One dose STZ at 135mg/kg body weight after preliminary screening)²⁰; (3) Con-FMT [STZ plus gut microbiota from control mice (Experiment I)]; (4) A10-FMT [STZ plus gut microbiota from AOS 10 mg/kg mice (Experiment I)]. STZ was injected at the beginning of the experiment. Then the mice were received oral FMT inoculations (0.1 ml) once daily for two weeks (five weeks of age to seven weeks of age). Then the mice were regularly maintained (on respective diet) for another three weeks (ten

weeks of age). Then, the mice were humanely euthanized to collect samples for different analyses (Fig. 1a; Study scheme).

Evaluation of spermatozoa motility using a computer-assisted sperm analysis

system. Spermatozoa motility was assessed using a computer-assisted sperm assay (CASA) method according to World Health Organization guidelines²². After euthanasia, spermatozoa were collected from the cauda epididymis of mice and suspended in DMEM/F12 medium with 10% FBS and incubated at 37.5 °C for 30 min; samples were then placed in a pre-warmed counting chamber. The micropic sperm class analyzer (CASA system) was used in this investigation. It was equipped with a 20-fold objective, a camera adaptor (Eclipse E200, Nikon, Japan), and a camera (acA780-75gc, Basler, Germany), and it was operated by an SCA sperm class analyzer (MICROPTIC S.L.). The classification of sperm motility was as follows: grade A linear velocity $>22 \mu\text{m s}^{-1}$; grade B $<22 \mu\text{m s}^{-1}$ and curvilinear velocity $>5 \mu\text{m s}^{-1}$; grade C curvilinear velocity $<5 \mu\text{m s}^{-1}$; and grade D = immotile spermatozoa. The spermatozoa motility data represented only grade A + grade B since only these two grades are considered to be functional.

Morphological observations of spermatozoa. The extracted murine caudal epididymides were placed in RPMI medium, finely chopped, and then Eosin Y (1%) was added for staining as described previously²². Spermatozoon abnormalities were then viewed using an optical microscope and were classified into head or tail morphological abnormalities: two heads, two tails, blunt hooks, and short tails. The examinations were repeated three times, and 500 spermatozoa per animal were scored.

Assessment of acrosome integrity. After harvest, mouse spermatozoa were incubated at 37.5 °C for 30 min, after which a drop of sperm suspension was uniformly smeared on a clean glass slide. Smeared slides were air dried and incubated

in methanol for 2 min for fixation. After fixation, the slides were washed with PBS three times. Assessment of an intact acrosome was accomplished by staining the sperm with 0.025% Coomassie brilliant blue G-250 in 40% methanol for 20 min at room temperature (RT). The slides were then washed three times with PBS and mounted with 50% glycerol in PBS. Acrosomal integrity was determined by an intense staining on the anterior region of the sperm head under bright-field microscopy (AH3-RFCA, Olympus, Tokyo, Japan) and scored accordingly²².

RNA Isolation and RNA-seq analyses²². Briefly, total RNA was isolated using TRIzol Reagent (Invitrogen) and purified using a Pure-Link1 RNA Mini Kit (Cat: 12183018A; Life Technologies) following the manufacturers' protocol. Total RNA samples were first treated with DNase I to degrade any possible DNA contamination. Then the mRNA was enriched using oligo(dT) magnetic beads. Mixed with the fragmentation buffer, the mRNA was broken into short fragments (about 200 bp), after which, the first strand of cDNA was synthesized using a random hexamer-primer. Buffer, dNTPs, RNase H, and DNA polymerase I were added to synthesize the second strand. The double strand cDNA was purified with magnetic beads. Subsequently, 3'-end single nucleotide A (adenine) addition was performed. Finally, sequencing adaptors were ligated to the fragments. The fragments were enriched by PCR amplification. During the QC step, an Agilent 2100 Bioanalyzer and ABI StepOnePlus Real-Time PCR System were used to qualify and quantify the sample library. The library products were prepared for sequencing in an Illumina HiSeqTM 2500. The reads were mapped to reference genes using SOAPaligner (v. 2.20) with a maximum of two nucleotide mismatches allowed at the parameters of “-m 0 -x 1000 -s 40 -l 35 -v 3 -r 2”. The read number of each gene was transformed into RPKM (reads per kilo bases per million reads), and then differentially expressed genes were

identified using the DEGseq package and the MARS (MA-plot-based method with random sampling model) method. The threshold was set as $FDR \leq 0.001$ and an absolute value of $\log_2$ ratio ≥ 1 to judge the significance of the difference in gene expression. Then on the data were analyzed by GO enrichment, KEGG enrichment.

Sequencing of microbiota from intestine digesta samples and data analysis²².

DNA Extraction. Total genomic DNA of small intestine, cecum and colon digesta was isolated using an E.Z.N.A.R Stool DNA Kit (Omega Bio-tek Inc., USA) following the manufacturer's instructions. DNA quantity and quality were analyzed using NanoDrop 2000 (Thermo Scientific, USA) and 1% agarose gel. Ten samples/groups were determined. **Library preparation and sequencing.** The V3-V4 region of the 16S rRNA gene was amplified using the primers MPRK341F (5'-ACTCCTACGGGAGGCAGCAG -30) and MPRK806R: (5'-GGACTACHVGGGTWTCTAAT -30) with Barcode. The PCR reactions (total 30 μ L) included 15 μ L PhusionR High-Fidelity PCR Master Mix (New England Biolabs), 0.2 mM primers, and 10 ng DNA. The thermal cycle was carried out with an initial denaturation at 98 °C, followed by 30 cycles of 98 °C for 10 s, 50 °C for 30 s, 72 °C for 30 s, and a final extension at 72 °C for 5 min. PCR products were purified using a GeneJET Gel Extraction Kit (Thermo Scientific, USA). The sequencing libraries were constructed with NEB NextR UltraTM DNA Library Prep Kit for Illumina (NEB, United States) following the manufacturer's instructions and index codes were added. Then, the library was sequenced on the Illumina HiSeq 2500 platform and 300 bp paired-end reads were generated at the Novo gene. The paired-end reads were merged using FLASH (V1.2.71). The quality of the tags was controlled in QIIME (V1.7.02), meanwhile all chimeras were removed. The "Core Set" of the Greengenes database³ was used for classification, and sequences with >97% similarity were assigned to the

same operational taxonomic units (OTUs). **Analysis of sequencing data** Operational taxonomic unit abundance information was normalized using a standard of sequence number corresponding to the sample with the least sequences. The alpha diversity index was calculated with QIIME (Version 1.7.0). The Unifrac distance was obtained using QIIME (Version 1.7.0), and PCoA (principal coordinate analysis) was performed using R software (Version 2.15.3). The linear discriminate analysis effect size (LEfSe) was performed to determine differences in abundance; the threshold LDA score was 4.0. GraphPad Prism7 software was used to produce the graphs.

Plasma and testis metabolite measurements by LC-MS/MS. Plasma samples were collected and immediately stored at -80 °C. Before LC-MS/MS analysis, the samples were thawed on ice and processed to remove proteins. Testis samples were collected and the same amount of tissue from each mouse testis was used to isolate the metabolites using CH₃OH: H₂O (V: V) = 4:1. Then samples were detected by ACQUITY UPLC and AB Sciex Triple TOF 5600 (LC/MS) as reported previously^{17,22}. Ten samples/groups were analyzed for plasma or testis samples. The HPLC conditions employed an ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm), solvent A [aqueous solution with 0.1% (v/v) formic acid], and solvent B [acetonitrile with 0.1% (v/v) formic acid] with a gradient program. The flow rate was 0.4 mL/min and the injection volume was 5 μL. Progenesis QI v2.3 (Nonlinear Dynamics, Newcastle, UK) was implemented to normalize the peaks. Then the Human Metabolome Database (HMDB), Lipidmaps (v2.3), and METLIN software were used to qualify the data. Moreover, the data were processed with SIMCA software (version 14.0, Umetrics, Umeå, Sweden) following pathway enrichment analysis using the KEGG database (<http://www.genome.jp/KEGG/pathway.html>).

Determination of blood glucose, insulin, ALT, TG, TC, T-AOC, GSH, SOD and

catalase. Blood insulin was determined by the kit from Beijing Solarbio Science & Technology Co., Ltd (Beijing, P. R. China; Cat. #: SEKM0141). Blood glucose, ALT, TG, TC, T-AOC, SOD, and catalase were determined by the kits from Nanjing Jiancheng Bioengineering Institute [Nanjing, P.R. China; glucose (Cat. #: F006-1-1); ALT (Cat. #: C009-2-1); TG (Cat. #: A110-1-1); TC (Cat. #: A111-1-1); T-AOC (Cat. #: A015-2-1); GSH (Cat. #: A006-2-1); SOD (Cat. #: A001-3-2); Catalase (Cat. #: A007-1-1)]²⁵. All the procedures were followed from the manufacturer's instructions.

Measurement of iron content in spleen. The amount of ferric iron in the spleens was determined by Perl's Prussian blue stain as described by Kohyama et al²⁶. Spleen tissues were fixed with 4% paraformaldehyde, then embedded in paraffin. And 5 µm sections were cut and stained with Perl's Prussian blue and pararosaniline (Sigma).

Histopathological analysis. Testicular tissues were fixed in 10% neutral buffered formalin, paraffin embedded, cut into 5 µm sections and subsequently stained with hematoxylin and eosin (H&E) for histopathological analysis.

Western blotting. Western blotting analysis of proteins was carried out as previously reported^{17,22}. Briefly, testicular tissue samples were lysed in RIPA buffer containing the protease inhibitor cocktail from Sangong Biotech, Ltd. (Shanghai, China). Protein concentration was determined using a BCA kit (Beyotime Institute of Biotechnology, Shanghai, China). Goat anti-actin was used as a loading control. The information for primary antibodies (Abs) were listed in [Supplementary Table 1](#). Secondary donkey anti-goat Ab (Cat no.: A0181) was purchased from Beyotime Institute of Biotechnology, and goat anti-rabbit (Cat no.: A24531) Abs were bought from Novex[®] by Life Technologies (USA). Fifty micrograms of total protein per sample were loaded onto 10% SDS polyacrylamide electrophoresis gels. The gels were transferred to a polyvinylidene fluoride (PVDF) membrane at 300 mA for 2.5 h at 4 °C. The

membranes were then blocked with 5% bovine serum albumin (BSA) for 1 h at RT, followed by three washes with 0.1% Tween-20 in TBS (TBST). The membranes were incubated with primary Abs diluted with 1:500 in TBST with 1% BSA overnight at 4 °C. After three washes with TBST, the blots were incubated with the HRP-labelled secondary goat anti-rabbit or donkey anti-goat Ab respectively for 1 h at RT. After three washes, the blots were imaged. The bands were quantified using Image-J software. The intensity of the specific protein band was normalized to actin first, then the data were normalized to the control. The experiment was repeated >6 times.

Detection of protein levels and location in testis using immunofluorescence

staining. The methodology for immunofluorescence staining of testicular samples is reported in our recent publications^{17,22}. Sections of testicular tissue (5 µm) were prepared and subjected to antigen retrieval and immunostaining as previously described^{17,22}. Briefly, sections were first blocked with normal goat serum in PBS, followed by incubation with primary Abs ([Supplementary Table 1](#); 1:100 in PBS-0.5% Triton X-100; Bioss Co. Ltd. Beijing, PR China) at 4 °C overnight. After a brief wash, sections were incubated with an Alexa 546-labeled goat anti-rabbit secondary Ab (1:100 in PBS; Molecular Probes, Eugene, OR, USA) at RT for 30 min and then counterstained with 4',6-diamidino-2-phenylindole (DAPI). The stained sections were examined using a Leica Laser Scanning Confocal Microscope (LEICA TCS SP5 II, Germany). Ten animal samples from each treatment group were analysed. Positively stained cells were counted. A minimum of 1000 cells were counted for each sample of each experiment. The data were then normalized to the control.

Statistical analysis. Data were analyzed using SPSS statistical software (IBM Co., NY) with one-way analysis of variance (ANOVA) followed by LSD multiple comparison tests or T-test. The data were shown as the mean ± SEM. Statistical

significance was based on $p < 0.05$.

Data availability

Liver and spleen RNA-seq raw data were deposited in NCBI's Gene Expression Omnibus under accession number GSE184021 and GSE184023, respectively. The microbiota raw sequencing data generated in this study has been uploaded to the NCBI SRA database with the accession number PRJNA759114 (small intestine), PRJNA759089 (cecum), and PRJNA759063 (colon).

Results

A10-FMT decreased blood glucose, ameliorated STZ-induced T1D diminished semen quality, and impaired gut microbiota

Three days after STZ treatment (one dose, 135 mg/kg body weight), blood glucose was significantly higher in the STZ group [23.8 ± 2.1 mmol/L (mM)] than that in the control group (Con; 8.2 ± 1.3 mM) which indicated that the animals were diabetic (T1D; Fig. 1a; Study scheme). After five weeks treatment, the body weight and blood insulin were lower in STZ group than that in Con, while FMT from AOS improved gut microbiota (A10-FMT) produced a slight increase in body weight and blood insulin over STZ [no significant difference between STZ, A10-FMT, and FMT from gut microbiota of control animals (Con-FMT); Supplementary Fig. 1a and b]. After five weeks of treatment, blood glucose was significantly higher in STZ while it was significantly decreased by A10-FMT and Con-FMT (Fig. 1b) which indicated that FMT treatment improved T1D status⁸. At the same time blood glycogen was higher in STZ animals while it was reduced by A10-FMT but not Con-FMT (Fig. 1c), which further suggested that A10-FMT improved T1D status. STZ significantly diminished semen quality through decreasing sperm motility and concentration (Fig. 1d and e). However, A10-FMT significantly increased sperm motility and concentration, while

Con-FMT produced a slight change (Fig. 1d and e). The data suggest that A10-FMT contained beneficial microbiota for improving semen quality.

Gut dysbiosis has been reported in both T1D humans and animal models⁹⁻¹¹. Moreover, dysbiosis may also impair spermatogenesis to decrease semen quality. In the current investigation, we found a similar phenomenon as the microbiota in the small intestine, cecum, and colon were changed in T1D animals with an increase in the harmful bacteria *Bacteroides*, *Mycoplasma*, and *Escherichia*^{8,12} (Fig. 2; Fig. 3; Supplementary Fig. 1c-n). A10-FMT increased the beneficial microbiota *Lactobacillus* in the small intestine, while decreasing the harmful bacteria *Escherichia* in the cecum and colon (Fig. 2d and h; Fig. 3d; Supplementary Fig. 1c-n). However, Con-FMT decreased *Bacteroides*, *Mycoplasma*, and *Escherichia*, but did not increase *Lactobacillus* (Fig. 2; Fig. 3; Supplementary Fig. 1c-n).

The gut microbiota participates in host metabolism by interacting with host signaling pathways. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of changed microbiota genes found that 12 major signaling pathways were upset by STZ and recovered by A10-FMT and/or Con-FMT in the colon, cecum, and/or small intestine (Fig. 3e). Interestingly, the “biosynthesis of other secondary metabolites” pathway was increased by A10-FMT specifically in the colon, and the “energy metabolism” pathway was decreased by STZ while increased by A10-FMT in the colon; meanwhile, the “carbohydrate metabolism” pathway was increased by A10-FMT while decreased by Con-FMT in the small intestine (Fig. 3e). However, the “metabolism of terpenoids and polyketides”, “amino acid metabolism”, and “lipid metabolism” pathways were only increased by Con-FMT in the cecum; the “carbohydrate metabolism” pathway was decreased only by Con-FMT in the colon; and the “cell motility” pathway was only increased by Con-FMT in the small intestine

(Fig. 3e). Moreover, the “Energy metabolism” pathway in the cecum, “amino acid metabolism” pathway in the small intestine, and “metabolism of cofactor and vitamins” pathway in the small intestine were decreased by both A10-FMT and Con-FMT, while they were not changed by STZ; “membrane transport” pathway in the cecum, and “metabolism of other amino acids” and “lipid metabolism” in the small intestine were increased by both A10-FMT and Con-FMT while they remained unchanged by STZ; “xenobiotics biodegradation and metabolism” was decreased by STZ while increased by both A10-FMT and Con-FMT (Fig. 3e). The data indicated that A10-FMT and Con-FMT differentially modified gut microbiota and microbial function to affect blood metabolites and other processes such as spermatogenesis.

A10-FMT-recovered gut microbiota improved the blood metabolome

T1D is a metabolic related disease, and gut microbiota influence the blood metabolome; therefore, we next explored blood metabolome changes using LC/MS (Data Set 1). KEGG enrichment analysis of changed microbiota genes indicated that the “carbohydrate metabolism” pathway was increased by A10-FMT in the small intestine, and it was interesting to note that blood carbohydrate was increased by STZ while decreased by A10-FMT or Con-FMT (Fig. 4a).

Two other large clusters of compounds were decreased by STZ while increased by A10-FMT including flavonoids (Fig. 4b-d; Supplementary Fig. 2a), and glycerophosphocholines/ glycerophosphoethanolamines (Fig. 4e-h; Supplementary Fig. S2b-i). Flavonoids are compounds that play important roles in antioxidant activity and other functions to protect organisms. Glycerophosphocholines and glycerophosphoethanolamines have protective functions within the body.

In addition, melatonin, that has antioxidant effects along with many other functions, was decreased by STZ while increased by A10-FMT and Con-FMT (Fig.

4i) although at non-significant levels, which suggested that FMT could help increase systemic antioxidant capabilities. L-carnitine, an important compound involved in male sperm formation and function, was decreased by STZ while increased by A10-FMT but not by Co-FMT (Fig. 4j) which suggested that A10-FMT and Con-FMT differentially influence blood metabolism especially for antioxidant compound production. The data were consistent with gut microbiota data that A10-FMT increased *Lactobacillus* which have been shown to produce metabolites that improve liver or cardiac impairment²⁷⁻²⁹ (Fig. 3e). Most interestingly, blood n-3 polyunsaturated acid (PUFA) eicosapentaenoic acid (EPA) was decreased by STZ while increased by A10-FMT and Con-FMT (Fig. 4k). It is known that n-3 PUFA especially EPA and DHA are important for many aspects of our health, including spermatogenesis³⁰⁻³².

A10-FMT-improved blood metabolite ameliorated testicular metabolome (PUFA and retinoic acid) and the testicular microenvironment

The blood metabolome was upset in T1D (by STZ) while it recovered under treatment with A10-FMT and/or Con-FMT, which suggested that FMT creates beneficial systemic improvements in animals. Blood metabolites are important for testis growth and sperm development^{17,18,22}; the blood metabolome and testicular metabolome are connected together, therefore, we set out to determine the testicular metabolome using LC/MS.

It was notable that the testicular n-3 PUFAs DHA and EPA were increased by A10-FMT but not by Con-FMT (Fig. 5a-c; Supplementary Fig. 3a; Data Set 2), which further suggested that A10-FMT is beneficial for testicular metabolism. The retinoic acid pathway plays a crucial role in spermatogenesis^{33,34}; and PUFA and retinoic acid signaling interact together to regulate spermatogenesis^{35,36}. STZ decreased retinol or

retinoic acid related compounds while A10-FMT increased them (Fig. 5d and e; Supplementary Fig. 3b-d) which suggested that spermatogenesis was initiated by A10-FMT since retinoic acid turns meiosis on. Moreover, the protein levels of the spermatogonia cell marker genes PLZF and DAZL were elevated by A10-FMT (Fig. 5f) which confirmed initiation of the spermatogenesis process. Moreover, testosterone levels were increased by A10-FMT (Fig. 5g-i; Supplementary Fig. 3e-g); steroids other than testosterone were increased by A10-FMT while they were decreased by STZ (Fig. 5j and k; Supplementary Fig. 3h-l) which together further confirmed initiation of spermatogenesis. Similarly, in the blood, testicular glycerophosphocholines were increased by A10-FMT while they were decreased by STZ (Fig. 5l; Supplementary Fig. 3m-o). Melatonin metabolite 6-hydroxymelatonin, an active form of melatonin³⁷, was increased by A10-FMT (Fig. 5m) which indicated that A10-FMT modulated both the systemic antioxidant status and also the testicular microenvironment to benefit spermatogenesis.

A10-FMT-improved testicular microenvironment benefited spermatogenesis to improve semen quality

A10-FMT improved the testicular metabolome, especially through increased DHA and EPA which suggested that spermatogenesis should be improved. Spermatogenesis was indeed improved by A10-FMT (Fig. 6). The protein level (number of positive cells) of germ cell marker *VASA* (*DDX4*) was decreased in T1D animals while increased by A10-FMT (Fig. 6a and b). The protein level (number of positive cells) of the meiosis marker gene *SYCP3* was increased by A10-FMT while reduced by STZ (Fig. 6a and c). The protein level (number of positive cells) of transition protein 1 (*TPI*) was increased by A10-FMT (Fig. 6a and d). The protein level (number of positive cells) of the sperm protein *PGK2* was decreased by STZ while increased by

A10-FMT (Fig. 6a and e). Moreover, the protein levels of some of the important genes for spermatogenesis *CREM*, *B-MYB*, *PIWIL1*, *ODF1*, *PGK2*, and *TP1* were determined by Western blotting. It was noteworthy that all these proteins were elevated by A10-FMT (Fig. 6f and g) which confirmed the IHF data and also suggested that spermatogenesis was improved by A10-FMT. At the same time the Sertoli cell marker gene *SOX9* was detected by IHF; it was shown that the number of *SOX9* positive cells remained unchanged by STZ or A10-FMT compared to Con (Fig. 6h). The data suggested that STZ impaired germ cells, but not somatic cells, to diminish spermatogenesis.

Furthermore, A10-FMT-improved gut microbiota benefited spleen immune function and liver function to strengthen the systemic environment for spermatogenesis

The spleen plays vital roles in systemic immune function^{38,39}. Recently, it has been established that the gut microbiota is involved in spleen development and function^{38,39}; and a gut-spleen interaction (axis) has been identified. In the current investigation, STZ also disrupted spleen function. Spleen RNA-seq data showed that STZ upset spleen gene expression while this was recovered by A10-FMT and/or Con-FMT (Supplementary Fig. S4). Gene enrichment analysis also showed that functions upset by STZ were reversed by A10-FMT or Con-FMT (Fig.7a; Supplementary Fig. 4a and b). “Adapted immune response”, “Complement cascade”, and “Platelet activation”, “Complement and coagulation cascade”, and “hemostasis” functional pathways were enriched for the genes decreased by STZ while they were increased by A10-FMT, which indicated that the immune and vasculature systems may be affected by STZ and recovered by A10-FMT. The “hemostasis” functional pathway indicated that STZ affected blood supply to the spleen, and it was confirmed by the expression

of hemoglobin scavenger receptor (CD163) protein. CD163 is known to play major roles in the clearance and endocytosis of hemoglobin/haptoglobin complexes²⁶. STZ decreased CD163 protein levels in the spleen while these were recovered by A10-FMT (Fig.7b).

A10-FMT improved spleen immune functions. T-cell protein CCL21 and its receptor CCR7 play crucial roles in maintaining the active migratory state of T cells⁴⁰. STZ decreased CCL21 protein levels (or positive cells) in the spleen while this was reversed by A10-FMT but not Con-FMT (Fig.7c). At the same time, the protein levels (or positive cells) of CCR7 were reduced by STZ while they were recovered by A10-FMT but not Con-FMT (Fig.7d). Moreover, the spleen plays important roles in iron homeostasis through the resorption of effete erythrocytes and the subsequent return of iron to the circulation. Free iron has the potential to become cytotoxic when electron exchange with oxygen is unrestricted and catalyzes the production of reactive oxygen species. Therefore, the balance of iron in the spleen and circulation is very important for health^{26,41,42}. STZ increased the levels of iron in the spleen while this was reversed by A10-FMT but not Con-FMT (Fig.7e). Furthermore, the proliferation and apoptosis status of the spleen was recovered by A10-FMT (Supplementary Fig. 4c, d). The protein levels (or the number of positive cells) of cell proliferation marker Ki67 were reduced by STZ while they were increased by A10-FMT (Supplementary Fig. 4c). Furthermore, the protein levels of apoptosis markers p53 and Bax were diminished by STZ while they were recovered by A10-FMT (Supplementary Fig. 4d). All the data suggested that A10-FMT benefited spleen functions to assist with systemic immune functions since T1D is an important immune related disease¹.

The liver plays a vital role in glucose metabolism and detoxification and many other functions maintain homeostasis. STZ upset liver function while this was

recovered by A10-FMT ([Supplementary Fig. 5](#)). The liver damage marker alanine aminotransferase (ALT) was increased in the blood while this was decreased by A10-FMT ([Supplementary Fig. 5a](#)). RNA-seq analysis also showed that STZ disrupted liver functions while this was reversed by A10-FMT and/or Con-FMT ([Supplementary Fig. 5b-d](#)). KEGG enrichment analysis indicated that liver lipid metabolism was upset by STZ while it was reversed by A10-FMT and/or Con-FMT ([Supplementary Fig. 5c and d](#)). Furthermore, blood triglyceride (TG) and total cholesterol (TC) levels were increased by STZ while these were reversed by A10-FMT and/or Con-FMT ([Supplementary Fig. 5e and f](#)).

Antioxidants also play important roles in maintaining systemic functions. Blood total antioxidant capability (T-AOC) level was reduced by STZ while it was recovered by A10-FMT ([Supplementary Fig. 5g](#)). At the same time the levels of antioxidant enzymes SOD and catalase were decreased by STZ while increased by A10-FMT ([Supplementary Fig. 5h and i](#)). The antioxidant compound GSH was also increased by A10-FMT ([Supplementary Fig. 5j](#)). At the same time liver apoptosis status was upset by STZ while it was recovered by A10-FMT ([Supplementary Fig. 5k](#)). All the data suggested that A10-FMT had a strong capacity to improve levels of systemic antioxidants to benefit spermatogenesis since T1D induced hyperglycemia causes systemic oxidative stress⁴.

Discussion

Since gut dysbiosis and T1D are closely related, and 90% of male T1D patients have varying degrees of testicular dysfunction and male infertility; gut dysbiosis and male infertility are also correlated. As most male T1D patients are of reproductive age, it is worth exploring protocols for improving spermatogenesis and male fertility²¹. Many studies have used different procedures to increase fertility, such as resveratrol and

metformin, which are capable of improving semen quality to some extent^{20,21}. Very recently, we found that FMT from AOS-improved gut microbiota rescues high fat diet disrupted spermatogenesis. In the current investigation, we found that FMT from AOS-improved gut microbiota (A10-FMT), but not FMT from gut microbiota of control animals (Con-FMT), significantly increased sperm concentration and motility in STZ-induced T1D animals. Moreover, A10-FMT significantly decreased blood glucose and glycogen which suggested that A10-FMT may be supportive management for T1D patients.

Higher levels of gut *Bacteroidetes* have been found in T1D patients compared with their peers¹². We found similar results; *Bacteroidetes* was increased in the cecum and colon of STZ-induced T1D animals compared with control group. Both A10-FMT and Con-FMT decreased the amount of *Bacteroidetes*. Meanwhile, *Prevotella* has been found to be inversely related to pancreatic beta cell function, and *Desulfovibrio* to be positively correlated with beta cell function¹². In the current study, we found *Desulfovibrio* was decreased in the cecum of STZ-induced T1D animals while A10-FMT and Con-FMT restored its levels; *Prevotella* was increased in the colon of STZ-induced T1D animals while A10-FMT and Con-FMT decreased its levels. As these results show beneficial outcomes, this suggests that FMT could improve gut microbiota.

Of great interest in the current study was our finding that the small intestine *Lactobacillus* population, which has been shown to have multiple functions in human health^{27-29,43,44}, and is discussed below, was increased by A10-FMT but not by Con-FMT. *Lactobacillus plantarum* 299v is reported to improve vascular endothelial function and decrease systemic inflammation in men with coronary artery disease and it is suggested that circulating gut-derived metabolites likely account for these

improvements²⁷. *Lactobacillus helveticus* R0052 has anti-inflammatory properties through downregulating Toll-like receptors, tumor necrosis factor- α , and nuclear factor- κ b transcription in liver samples and decreasing proinflammatory cytokine plasma concentrations to alleviate hepatic injuries²⁸. Meanwhile, *L. helveticus* R0052 is known to improve carbohydrate and fatty acid metabolism and reduce lithocholic acid levels²⁸. Lew et al. report that some selected *Lactobacillus* strains improve lipid profiles via activation of energy and lipid metabolism, suggesting the potential of *Lactobacillus* spp. as promising natural interventions for the alleviation of cardiovascular and liver diseases²⁹. *Lactobacillus rhamnosus* GG ATCC53103 and *Lactobacillus plantarum* JL01, can improve growth performance and immunity of piglets, and relieve weaning stress-related immune disorders such as intestinal infections and inflammation⁴³. The enhanced immunity in the latter study took place through increasing levels of tauroursodeoxycholic acid (TCDA) and docosahexaenoic acid (DHA); however there was a simultaneous decrease in succinic and palmitic acids⁴³. *Lactobacillus plantarum* PCA 236 has been shown to beneficially modulate goat fecal microbiota and milk fatty acid composition⁴⁴. These studies indicate that *Lactobacillus* spp. have the capacity to modify the production of polyunsaturated fatty acids such as DHA in animal blood or other organs.

It is known that DHA is crucial for spermatogenesis and male reproductive functions³⁰⁻³²; it has also been shown that DHA supplementation can fully restore fertility and spermatogenesis in male mice³¹. Meanwhile, Gallardo et al. report that a high fat diet decreases testicular DHA levels, which may be related to the production of dysfunctional spermatozoa³². The identification of beneficial n-3 PUFAs in this study was enlightening; we suggest that DHA and EPA were increased by A10-FMT in the blood and testes which was correlated with the increase in *Lactobacillus* in the

small intestine following A10-FMT treatment. The current and previous studies have demonstrated that *Lactobacillus spp.* have the potential to improve DHA levels, which is important for aspects of health, including improvements in spermatogenesis. Furthermore, testosterone is a strategic player in spermatogenesis, and approximately 94.4% of diabetes cases are associated with hypotestosteronemia. Moreover, the incidence of sexual and reproductive dysfunction in diabetic patients is 5–10-fold higher than that in nondiabetic individuals²¹. In current study, A10-FMT increased the testicular testosterone levels, which may account for the improvement of spermatogenesis and semen quality.

T1D is an immune related disease, and perturbations in the gut microbiota can impair the functions of immune cells and vice-versa¹⁰. Such dysbiosis is often detected in T1D subjects, especially those with an adverse immunoresponse¹⁰. As an organ of immunity, the spleen plays important roles in our health³⁸; furthermore, it has been established that the gut-spleen axis affects spleen development and human health^{38,39}. In the current study, we found that STZ-induced T1D disrupted spleen function while A10-FMT rescued it through the improvement of immune cell function and iron levels. Free iron levels in the spleen or liver may potentially become cytotoxic as they can catalyze the production of reactive oxygen species (ROS)⁴¹. A10-FMT beneficially decreased spleen iron levels, reduced apoptosis protein levels, and increased cell proliferation marker ki67 levels, all of which indicate improvements in spleen function²⁶. Macrophages, indispensable immune cells, also play important roles in the regulation of spleen iron levels^{41,42}, which further suggests that A10-FMT improves spleen immune function. This improvement in spleen function may support systemic health and spermatogenesis.

The main characteristic of T1D is hyperglycemia which can induce oxidative

stress, increase endoplasmic reticulum stress, and impair mitochondrial function⁴. We found that STZ-induced T1D decreased T-AOC level and the levels of some antioxidant enzymes, such as SOD, while A10-FMT restored them. We also detected that STZ-induced T1D caused liver damage through increasing ALT levels, while A10-FMT recovered it. At the same time A10-FMT improved liver function by modulating the apoptotic status in liver cells.

In summary, in our animal model, STZ-induced T1D disrupted spermatogenesis to diminish semen quality through decreasing sperm concentration and sperm motility. Most importantly, STZ-induced T1D caused gut dysbiosis. A10-FMT and Con-FMT decreased blood glucose levels and improved gut microbiota through the reduction of “harmful” microbes and increase in “beneficial” microbes. Most importantly, A10-FMT enhanced specific beneficial microbiota such *Lactobacillus* to increase the production of n-3 PUFA, such as DHA and EPA, to ameliorate spermatogenesis and semen quality while Con-FMT did not. Moreover, A10-FMT specifically improved spleen and liver function to promote sperm development and increase semen quality. Thus, AOS improved gut microbiota may support the improvement of semen quality and male fertility in T1D patients.

Acknowledgements

We thank the investigators and staff of The Beijing Genomics Institute (BGI) and Shanghai LUMING Biotechnology CO., LCD for technical support. This study was supported by the National Natural Science Foundation of China (31772408 to YZ; 31672428 to HZ).

Author contributions

Y.H., Y.F., X.Y., L.C., R.Z., T.M., B.Y., H.H., Y. Zhou, X.T., S.W., L.L., P.Z., and B.H. performed the experiments and analyzed the data. Y. Zhao., H.Z., W.S., Q.S., Z.S., and Y.R. designed and supervised the study. Y. Zhao. and H.Z. wrote the manuscript. All the authors edited the manuscript and approved the final manuscript.

Competing interests

The authors declare no competing interests.

598 **References**

- 599 1. Mariño, E. et al. Gut microbial metabolites limit the frequency of autoimmune T
600 cells and protect against type 1 diabetes. *Nat. Immunol.* **18**(5), 552-562 (2017).
- 601 2. Gülden, E., Wongm F.S. & Wen L. The Gut Microbiota and Type 1 Diabetes. *Clin.*
602 *Immunol.* **159**(2), 143-53 (2015).
- 603 3. Barkabi-Zanjani, S., Ghorbanzadeh, V., Aslani, M., Ghalibafabbaghi, A., Chodari,
604 L. Diabetes mellitus and the impairment of male reproductive function: Possible
605 signaling pathways. *Diabetes Metab. Syndr.* **14**(5), 1307-1314 (2020).
- 606 4. Maresch, C.C., Stute, D.C., Alves, M.G., Oliveira, P.F., de Kretser, D.M. & Linn,
607 T. Diabetes-induced hyperglycemia impairs male reproductive function: a
608 systematic review. *Hum. Reprod. Update* **24**(1), 86-105 (2018).
- 609 5. La Vignera, S. et al. Reproductive function in male patients with type 1 diabetes
610 mellitus. *Andrology* **3**(6), 1082-1087 (2015).
- 611 6. Jangir, R.N. & Jain, G.C. Diabetes Mellitus Induced Impairment of Male
612 Reproductive Functions: A Review. *Curr. Diabetes Rev.* **10**(3), 147-157 (2014).
- 613 7. Glazer, C.H. et al. Risk of diabetes according to male factor infertility: a register-
614 based cohort study. *Hum. Reprod.* **32**(7), 1474-1481 (2017).
- 615 8. de Groot, P. et al. Faecal microbiota transplantation halts progression of human
616 new- onset type 1 diabetes in a randomized controlled trial. *Gut* **70**(1), 92-105
617 (2021).
- 618 9. Li, W.Z., Stirling, K., Yang, J.J. & Zhang, L. Gut microbiota and diabetes: From
619 correlation to causality and mechanism. *World J. Diabetes* **11**(7), 293-308
620 (2020).
- 621 10. Abdellatif, A.M. & Sarvetnick, N.E. Current understanding of the role of gut
622 dysbiosis in type 1 diabetes. *J. Diabetes* **11**(8), 632-644 (2019).
- 623 11. Neuman, V. et al. Human gut microbiota transferred to germ-free NOD mice
624 modulate the progression towards type 1 diabetes regardless of the pace of beta
625 cell function loss in the donor. *Diabetologia* **62**(7), 1291-1296 (2019).
- 626 12. Knip, M. & Siljander, H. The role of the intestinal microbiota in type 1 diabetes
627 mellitus. *Nat. Rev. Endocrinol.* **12**(3), 154-167 (2016).
- 628 13. Knip, M. & Honkanen, J. Modulation of Type 1 Diabetes Risk by the Intestinal
629 Microbiome. *Curr. Diab. Rep.* **17**(11): 105 (2017).
- 630 14. Wen, L. et al. Innate immunity and intestinal microbiota in the development of

- 631 Type 1 diabetes. *Nature* **455**(7216), 1109-1113 (2008).
- 632 15. Kostic, A.D. et al. The Dynamics of the Human Infant Gut Microbiome in
633 Development and in Progression towards Type 1 Diabetes. *Cell Host Microbe*
634 **17**(2), 260-273 (2015).
- 635 16. Ding, N. et al. Impairment of spermatogenesis and sperm motility by the high- fat
636 diet- induced dysbiosis of gut microbes. *Gut* **69**, 1608-1619 (2020).
- 637 17. Zhang, P. et al. Improvement in sperm quality and spermatogenesis following
638 fecal microbiota transplantation from alginate oligosaccharide dosed mice. *Gut*
639 **70**, 222-225 (2021).
- 640 18. Zhang, C. et al. Rescue of male fertility following fecal microbiota transplantation
641 from alginate oligosaccharide dosed mice. *Gut* **70**(11), 2213-2215 (2021).
- 642 19. Zhang, T. et al. Disrupted spermatogenesis in a metabolic syndrome model: the
643 role of vitamin A metabolism in the gut-testis axis. *Gut* (2021), doi:
644 10.1136/gutjnl-2020-323347.
- 645 20. Simas, J.N., Mendes, T.B., Paccola, C.C., Vendramini, V. & Miraglia, S.M.
646 Resveratrol attenuates reproductive alterations in type 1 diabetes-induced rats.
647 *Int. J. Exp. Pathol.* **98**(6), 312-328 (2017).
- 648 21. Liu, Y., Yang, Z., Kong, D., Zhang, Y., Yu, W. & Zha, W. Metformin Ameliorates
649 Testicular Damage in Male Mice with Streptozotocin-Induced Type 1 Diabetes
650 through the PK2/PKR Pathway. *Oxid. Med. Cell Longev.* **2019**, 5681701 (2019).
- 651 22. Zhao, Y. et al. Alginate oligosaccharides improve germ cell development and
652 testicular microenvironment to rescue busulfan disrupted spermatogenesis.
653 *Theranostics* **10**, 3308-3324 (2020).
- 654 23. Bárcena, C. et al. Healthspan and lifespan extension by fecal microbiota
655 transplantation into progeroid mice. *Nat. Med.* **25**, 1234-1242 (2019).
- 656 24. Brunse, A. et al. Effect of fecal microbiota transplantation route of administration
657 on gut colonization and host response in preterm pigs. *ISME J.* **13**, 720-773
658 (2019).
- 659 25. Chu, M. et al. MicroRNA-221 may be involved in lipid metabolism in mammary
660 epithelial cells. *Int. J. Biochem. Cell Biol.* **97**, 118-127 (2018).
- 661 26. Kohyama, M. et al. Role for Spi-C in the development of red pulp macrophages
662 and splenic iron homeostasis. *Nature* **457**, 318-321 (2009).
- 663 27. Malik, M. et al. Lactobacillus Plantarum 299v Supplementation Improves
664 Vascular Endothelial Function and Reduces Inflammatory Biomarkers in Men

- 665 with Stable Coronary Artery Disease. *Circ. Res.* **123**(9), 1091-1102 (2018).
- 666 28. Wang, Q. et al. Lactobacillus helveticus R0052 alleviates liver injury by
667 modulating gut microbiome and metabolome in D -galactosamine-treated rats.
668 *Appl. Microbiol. Biotechnol.* **103**(23-24), 9673-9686 (2019).
- 669 29. Lew, L. et al. Lactobacillus Strains Alleviated Hyperlipidemia and Liver Steatosis
670 in Aging Rats via Activation of AMPK. *Int. J. Mol. Sci.* **21**(16), 5872 (2020).
- 671 30. Hale, B.J. et al. Acyl-CoA synthetase 6 enriches seminiferous tubules with the n-3
672 fatty acid docosahexaenoic acid and is required for male fertility in the mouse. *J.*
673 *Biol. Chem.* **294**(39), 14394-14405 (2019).
- 674 31. Roqueta-Rivera, M. et al. Docosahexaenoic acid supplementation fully restores
675 fertility and spermatogenesis in male delta-6 desaturase-null mice. *J. Lipid. Res.*
676 **51**(2), 360-367 (2010).
- 677 32. Bunay, J. et al. A decrease of docosahexaenoic acid in testes of mice fed a high-fat
678 diet is associated with impaired sperm acrosome reaction and fertility. *Asian J.*
679 *Androl.* **23**(3), 306-313 (2021).
- 680 33. Griswold, M.D. Spermatogenesis: The commitment to meiosis. *Physiol. Rev.* **96**,
681 1-17 (2016).
- 682 34. Bowles, J. et al. Retinoid signaling determines germ cell fate in mice. *Science* **312**,
683 596-600 (2006).
- 684 35. Wolf, G. Is 9-cis-retinoic acid the endogenous ligand for the retinoic acid-X
685 receptor? *Nutr. Rev.* **64**, 532-538 (2006).
- 686 36. Lengqvist, J. et al. Polyunsaturated fatty acids including docosahexaenoic and
687 arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain.
688 *Mol. Cell Proteomics* **3**, 692-703 (2004).
- 689 37. Maharaj, D.S. et al. 6-Hydroxymelatonin protects against quinolinic-acid-induced
690 oxidative neurotoxicity in the rat hippocampus. *J. Pharm. Pharmacol.* **57**(7),
691 877-881 (2005).
- 692 38. Rosado, M.M. et al. Spleen development is modulated by neonatal gut microbiota.
693 *Immunol. Lett* **199**, 1-15 (2018).
- 694 39. Carsetti, R. et al. Lack of Gut Secretory Immunoglobulin A in Memory B-Cell
695 Dysfunction-Associated Disorders: A Possible Gut-Spleen Axis. *Front. Immunol.*
696 **10**, 2937 (2020).
- 697 40. den Haan, J.M., Mebius, R.E. & Kraal, G. Stromal cells of the mouse spleen.
698 *Front. Immunol.* **3**, 201 (2012).

- 699 41. Soares, M.P. & Hamza, I. Macrophages and Iron Metabolism. *Immunity* **44**, 492-
700 504 (2016).
- 701 42. Gammella, E., Buratti, P., Cairo, G. & Recalcati, S. Macrophages: central
702 regulators of iron balance. *Metallomics* **6**, 1336-1345 (2014).
- 703 43. Geng, T. et al. Probiotics Lactobacillus rhamnosus GG ATCC53103 and
704 Lactobacillus plantarum JL01 induce cytokine alterations by the production of
705 TCDA, DHA, and succinic and palmitic acids, and enhance immunity of weaned
706 piglets. *Res. Vet. Sci.* **137**, 56-67 (2021).
- 707 44. Maragkoudakis, P.A. et al. Feed supplementation of Lactobacillus plantarum PCA
708 236 modulates gut microbiota and milk fatty acid composition in dairy goats — a
709 preliminary study. *Int. J. Food Microbiol.* **141** (Suppl 1), S109-16 (2010).

Figure legends

Fig. 1. A10-FMT decreased blood glucose, and improved semen quality in type 1

diabetes. a Blood glucose levels. The y-axis represents the concentration (mmol/L).

The x-axis represents the treatment (n = 30/group). * $p < 0.05$. **b** Blood glycogen

levels. The y-axis represents the relative amount. The x-axis represents the treatment

(n = 30/group). * $p < 0.05$. **c** Sperm concentration. The y-axis represents the

concentration. The x-axis represents the treatment (n = 30/group). * $p < 0.05$. **d** Sperm

motility. The y-axis represents the percentage of cells. The x-axis represents the

treatment (n = 30/group). * $p < 0.05$.

Fig. 2. A10-FMT improved small intestinal and cecal microbiota in type 1

diabetes. a PLS-DA (OTU) of small intestine microbiota in HFD, A10-FMT, and

Con-FMT groups. **b** Small intestine microbiota levels at the genus level in STZ, A10-

FMT, and Con-FMT groups. The y-axis represents the relative amount (%). The x-

axis represents the treatments. Different colors represent different microbiota. **c**

Cladogram of the linear discriminate analysis effect size (LEfSe) determining the

difference in abundance of small intestine microbiota. **d** Changed microbiota in the

small intestine. The y-axis represents the relative amount at the genus level. The x-

axis represents the treatment. * $p < 0.05$. **e** PLS-DA (OTU) of cecum microbiota in

STZ, A10-FMT, and Con-FMT groups. **f** Cecum microbiota levels at the genus level

in STZ, A10-FMT, and Con-FMT groups. The y-axis represents the relative amount

(%). The x-axis represents the treatments. Different colors represent different

microbiota. **g** Cladogram of the LEfSe determining the cecum microbiota difference

in abundance. **h** Changed microbiota in the cecum. The y-axis represents the relative

amount at the genus level. The x-axis represents the treatment. * $p < 0.05$.

Fig. 3. A10-FMT improved colon microbiota in type 1 diabetes. a PLS-DA (OTU)

of colon microbiota in STZ, A10-FMT, and Con-FMT groups. **b** Colon microbiota levels at the genus level in STZ, A10-FMT, and Con-FMT groups. The y-axis represents the relative amount (%). The x-axis represents the treatments. Different colors represent different microbiota. **c** Cladogram of the LEfSe determining the difference in abundance of colon microbiota. **d** Changed microbiota in the colon. The y-axis represents the relative amount at the genus level. The x-axis represents the treatment. $*p < 0.05$. **e** Summary of signaling pathways of changed microbiota genes by Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Red arrow indicates increased microbiota genes in each comparison. Blue arrow indicates decreased microbiota genes in each comparison.

Fig. 4. A10-FMT improved blood metabolism. **a** Blood carbohydrate levels in different treatments. The y-axis represents the fold change compared to control group (Con). The x-axis represents the treatment. **b** Blood flavonoid Kola flavanone levels in different treatments. The y-axis represents the relative amount. The x-axis represents the treatment. $*p < 0.05$. **c** Blood flavonoid Psoralenol levels in different treatments. The y-axis represents the relative amount. The x-axis represents the treatment. $*p < 0.05$. **d** Blood flavonoid 8-hydroxyapigenin 8-(2''-sulfatoglucuronide) levels in different treatments. The y-axis represents the relative amount. The x-axis represents the treatment. $*p < 0.05$. **e** Blood PC (17:1(9z)/0:0) levels in different treatments. The y-axis represents the relative amount. The x-axis represents the treatment. $*p < 0.05$. **f** Blood PC (17:0/0:0) levels in different treatments. The y-axis represents the relative amount. The x-axis represents the treatment. $*p < 0.05$. **g** Blood LysoPC (16:0) levels in different treatments. The y-axis represents the relative amount. The x-axis represents the treatment. $*p < 0.05$. **h** Blood LysoPC (18:0) levels in different treatments. The y-axis represents the relative amount. The x-axis represents

760 the treatment. $^*p < 0.05$. **i** Blood melatonin levels in different treatments. The y-axis
 761 represents the relative amount. The x-axis represents the treatment. $^*p < 0.05$. **j** Blood
 762 L-Carnitine levels in different treatments. The y-axis represents the relative amount.
 763 The x-axis represents the treatment. $^*p < 0.05$. **k** Blood eicosapentaenoic acid (EPA)
 764 levels in different treatments. The y-axis represents the relative amount. The x-axis
 765 represents the treatment. $^*p < 0.05$.

766 **Fig. 5. A10-FMT improved testicular metabolism.** **a** Testicular docosahexaenoic
 767 acid (DHA) levels in different treatments. The y-axis represents the relative amount.
 768 The x-axis represents the treatment. **b** Testicular EPA in different treatments. The y-
 769 axis represents the relative amount. The x-axis represents the treatment. $^*p < 0.05$. **c**
 770 Testicular 9-hydroxy-2Z,5E,7Z,11Z,14Z-Eicosapentaenoic acid levels in different
 771 treatments. The y-axis represents the relative amount. The x-axis represents the
 772 treatment. $^*p < 0.05$. **d** Testicular 4-oxo-Retinoic acid levels in different treatments.
 773 The y-axis represents the relative amount. The x-axis represents the treatment. $^*p <$
 774 0.05 . **e** Testicular 9-cis-retinal levels in different treatments. The y-axis represents the
 775 relative amount. The x-axis represents the treatment. $^*p < 0.05$. **f** Testicular protein
 776 levels of *PLZF* and *DAZL* in different treatments determined by Western blotting. **g**
 777 Testicular testosterone isocaproate levels in different treatments. The y-axis represents
 778 the relative amount. The x-axis represents the treatment. $^*p < 0.05$. **h** Testicular
 779 testosterone glucuronide levels in different treatments. The y-axis represents the
 780 relative amount. The x-axis represents the treatment. $^*p < 0.05$. **i** Testicular 7alpha-
 781 hydroxytestosterone levels in different treatments. The y-axis represents the relative
 782 amount. The x-axis represents the treatment. $^*p < 0.05$. **j** Testicular stenbolone levels
 783 in different treatments. The y-axis represents the relative amount. The x-axis
 784 represents the treatment. $^*p < 0.05$. **k** Testicular cortisol 21-acetate levels in different

treatments. The y-axis represents the relative amount. The x-axis represents the treatment. $^*p < 0.05$. **l** Testicular PC (16:0/5:1(4E)) levels in different treatments. The y-axis represents the relative amount. The x-axis represents the treatment. $^*p < 0.05$. **m** Testicular 6-hydroxymelatonin levels in different treatments. The y-axis represents the relative amount. The x-axis represents the treatment. $^*p < 0.05$.

Fig. 6. A10-FMT improved spermatogenesis process. **a** IHF staining of testicular germ cell marker *VASA*, meiosis marker *SYCP3*, sperm protein *PGK2*, and transition protein 1 (*TP1*) in each treatment. Scale bar: 50 μ m. **b** Quantitative data for *VASA* IHF staining. The y-axis represents the percentage of total cell. The x-axis represents the treatment. $^*p < 0.05$. **c** Quantitative data for *SYCP3* IHF staining. The y-axis represents the percentage of total cell. The x-axis represents the treatment. $^*p < 0.05$. **d** Quantitative data for *TP1* IHF staining. The y-axis represents the percentage of total cell. The x-axis represents the treatment. $^*p < 0.05$. **e** Quantitative data for *PGK2* IHF staining. The y-axis represents the percentage of total cells. The x-axis represents the treatment. $^*p < 0.05$. **f** Western blotting analysis of the proteins of important genes for spermatogenesis in each treatment. **g** Quantitative data for Western blotting analysis. **h** IHF staining of Sertoli cell marker *SOX9*.

Fig. 7. A10-FMT improved spleen function. **a** Functional enrichment analysis of STZ decreased genes while they were increased by A10-FMT or Con-FMT. **b** IHF staining of *CD163* in spleen tissue. **c** IHF staining of *CCL21* in spleen tissue. **d** IHF staining of *CCR7* in spleen tissue. **e** Perl's Prussian blue stain for ferric iron in spleen tissue.

Supplementary information

Supplementary Fig. 1. Body weight and gut microbiota changes (STZ vs. Con). **a**

Animal bodyweight. The y-axis represents the body weight (g). The x-axis represents the age (weeks). **b** Blood insulin levels. The y-axis represents the concentration (mIU/L). The x-axis represents the treatment. **c** The alpha index of the small intestine microbiota (Chao index). The y-axis represents the relative amount. The x-axis represents the treatment. **d** The beta index of small intestinal microbiota. The y-axis represents the relative amount. The x-axis represents the treatment. **e** PLS-DA (OTU) of small intestine microbiota in STZ and Con groups. **f** Small intestine microbiota levels at the genus level in STZ and Con groups. The y-axis represents the relative amount (%). The x-axis represents the individual microbiota. **g** The alpha index of the cecum microbiota (Chao index). The y-axis represents the relative amount. The x-axis represents the treatment. **h** The beta index of cecum microbiota. The y-axis represents the relative amount. The x-axis represents the treatment. **i** PLS-DA (OTU) of cecum microbiota in STZ and Con groups. **j** Cecum microbiota levels at the genus level in STZ and Con groups. The y-axis represents the relative amount (%). The x-axis represents the individual microbiota. **k** The alpha index of the colon microbiota (Chao index). The y-axis represents the relative amount. The x-axis represents the treatment. **l** The beta index of colon microbiota. The y-axis represents the relative amount. The x-axis represents the treatment. **m** PLS-DA (OTU) of colon microbiota in STZ and Con groups. **n** Colon microbiota levels at the genus level in STZ and Con groups. The y-axis represents the relative amount (%). The x-axis represents the individual microbiota.

Supplementary Fig. 2. Blood metabolism changes. **a** Blood flavonoid Malvidin 3-

O-(6-O-(4-O-feruloyl-alpha-rhamnopyranosyl)-beta-glucopyranoside)-5-beta-glucopy

-ranoside levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **b** Blood glycerophosphocholine levels in different treatments. The y-axis represents the fold change compared to control group (Con). The x-axis represents the treatment. **c** Blood LysoPC (15:0) levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **d** Blood LysoPC [18:1(9z)] levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **e** Blood LysoPC [22:6(4Z,7Z,10Z,13Z,16Z,19Z)] levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **f** Blood PE [22:2(13Z,16Z)/0:0] levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **g** Blood PE (22:0/0:0) levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **h** Blood PE [22:1(11Z)/0:0] levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **i** Blood LysoPE [0:0/24:6(6Z,9Z,12Z,15Z,18Z,21Z)] levels. The y-axis represents the relative amount (%). The x-axis represents the treatments.

Supplementary Fig. 3. Testicular metabolite changes. **a** Testicular 4,8,12,15,18-eicosapentaenoic acid levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **b** Testicular retinoids levels in different treatments. The y-axis represents the fold change compared to the control group (Con). The x-axis represents the treatment. **c** Testicular retinol levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **d** Testicular retinyl ester levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **e** Testicular testosterone levels in different treatments. The y-axis represents the fold change compared to control group (Con). The x-axis represents the treatment. **f** Testicular testosterone propionate levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **g** Testicular testosterone

acetate levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **h** Testicular steroids levels in different treatments. The y-axis represents the fold change compared to control group (Con). The x-axis represents the treatment. **i** Testicular 3b,17b-Dihydroxyetiocholanolone levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **j** Testicular 5-Androstene-3b,16b,17a-triol levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **k** Testicular 3beta,17alpha,21-Trihydroxy-pregnenone levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **l** Testicular androstenediol levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **m** Testicular PCs levels in different treatments. The y-axis represents the fold change compared to the control group (Con). The x-axis represents the treatment. **n** Testicular PC(4:0/18:1(9Z)) level. The y-axis represents the relative amount (%). The x-axis represents the treatments. **o** Testicular PC (8:0/8:0) levels. The y-axis represents the relative amount (%). The x-axis represents the treatments.

Supplementary Fig. 4. Additional data for spleen. **a** PCA for RNA-seq analysis of spleen. **b** The functional enrichment analysis of STZ increased genes while these were decreased by A10-FMT or Con-FMT. **c** IHF staining of *ki67* in the spleen. **d** Western blotting analysis of *p53*, *Bax* and *Bcl-xl* in the spleen.






Supplementary Fig. 5. A10-FMT improved liver function and systemic anti-oxidative capability. **a** Blood alanine aminotransferase (ALT) levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **b** PCA for RNA-seq analysis of liver. **c** The functional enrichment analysis of STZ decreased genes while these were increased by A10-FMT or Con-FMT in the liver. **d** The functional enrichment analysis of STZ increased genes while these were decreased by









A10-FMT or Con-FMT in the liver. **e** Blood total triglyceride (TG) levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **f** Blood total cholesterol (TC) levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **g** Blood total antioxidant capability (T-AOC) levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **h** Blood total SOD levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **i** Blood catalase levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **j** Blood glutathione levels. The y-axis represents the relative amount (%). The x-axis represents the treatments. **k** Western blotting analysis of *Bax* and *Bcl-xl* in the liver.



Supplementary Table 1. Primary antibody information.

Data Set 1. Blood metabolites raw data.

Data Set 2. Testicular metabolites raw data.


a**b****c****d****e**


a**b****c****d****e****f****g****h**












e

	Small intestine			Cecum			Colon		
	STZ /Con	A10-FMT /STZ	Con-FMT /STZ	STZ /Con	A10-FMT /STZ	Con-FMT /STZ	STZ /Con	A10-FMT /STZ	Con-FMT /HSTZ
Biosynthesis of other secondary metabolites	↑	—	—	↓	↓	—	—	↑	—
Metabolism of terpenoids and polyketides	↓	↓	↓	—	—	↑	↑	↑	↑
Energy metabolism	↓	↓	↓	—	↓	↓	↓	↑	—
Glycan biosynthesis and metabolism	↑	—	—	↓	↓	↓	↓	—	↓
Membrane transport	↑	↑	—	—	↑	↑	↑	↑	—
Xenobiotics biodegradation and metabolism	↓	↑	↑	↓	—	—	—	—	—
Amino acid metabolism	—	↓	↓	—	—	↑	—	—	—
Carbohydrate metabolism	—	↑	↓	—	—	—	—	—	↓
Metabolism of other amino acid	—	↑	↑	↓	—	↓	↓	—	—
Metabolism of cofactors and vitamins	—	↓	↓	↓	↓	↓	↓	—	↓
Lipid metabolism	—	↑	↑	—	—	↑	↑	—	↑
Cell motility	—	—	↑	↑	↑	↑	↑	—	—









a**b**


CD163/Nuclei

**c**

CCL21/Nuclei

**d**

CCR7/Nuclei

**e**

Iron/Nuclei

